Search
DDP-225 free base anhydrous
go.drugbank.com/drugs/DB18047ExperimentalSynonyms: DDP-225 free base anhydrousCDD-0102
go.drugbank.com/drugs/DB16945ExperimentalSynonyms: Cdd-0102 free base, Mcd-386cr free baseCategories: Receptor, Muscarinic M1, agonistsCarbamide peroxide
go.drugbank.com/drugs/DB11129ApprovedInvestigationalof this ingredient as an oral wound healing agent [L1976]. … As it is a source of hydrogen peroxide, it can be found in disinfecting and dental bleaching products.
Products: Dr.Whitiss 10%, Endoperox 100%Tyrosine
go.drugbank.com/drugs/DB00135ApprovedInvestigationalNutraceuticalTyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
Mixtures: EAS ORAL 100 TABLET, TRAVASOL® SOLUCION BAL 8.5% SIN ELECTROLITOSPromazine
go.drugbank.com/drugs/DB00420ApprovedVet approvedWithdrawnIt is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
Synonyms: N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine, 10-(3-(Dimethylamino)propyl)phenothiazineCategories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsStanozolol
go.drugbank.com/drugs/DB06718ApprovedVet approvedStanozolol is derived from testosterone, and has been abused by several high profile professional athletes.
Products: STANOBON 10, สตาโนบอน 10Fluorodopa (18F)
go.drugbank.com/drugs/DB13848ApprovedInvestigationalFluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.
Products: Dopaview 222 MBq/ml Injektionslösung, IASOdopa 0,3 GBq/ml - Konzentrat zur Herstellung einer InjektionslösungIotrolan
go.drugbank.com/drugs/DB09487ApprovedWithdrawnNonionic, isotonic contrast medium designed for intrathecal use.
International brands: Osmovist 190Products: Osmovist 300 - Liq Int 641mg/ml, Osmovist 240 - Liq Int 513mg/mlMosunetuzumab
go.drugbank.com/drugs/DB15434ApprovedInvestigational[A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel … [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]
Products: Lunsumio 1mg/ml Concentrate for Solution for Infusion